Device Guide
Shurink, Ultraformer MPT, Doublo Gold — how Korean HIFU devices compare to Ultherapy. Technical specs, clinical data, and which device fits your goals.
Your Journey
Shurink, Ultraformer MPT, Doublo Gold — how Korean HIFU devices compare to Ultherapy. Technical specs, clinical data, and which device fits your goals.
South Korea's aesthetic dermatology market is one of the largest in the world, and domestic HIFU device manufacturers have built a parallel ecosystem to the US-dominated Ultherapy market.
Classys, the maker of Ultraformer (branded as Shurink in Korea), reported 2024 revenue of approximately KRW 242.9 billion (~USD 170 million), a 34% year-over-year increase, with over 2,000 Ultraformer MPT units cumulatively installed across Korean clinics. Hironic, maker of Doublo, has logged over 1 million clinical cases since 2011.
The Korean approach to HIFU differs from Western practice in important ways. Korean patients typically receive treatments every 3–6 months as maintenance, compared to the Western approach of a single annual session. This high-frequency model drives device design toward faster treatment, lower pain, and lower cost per session.
For international patients visiting Seoul, this means access to devices and treatment protocols that simply aren't available in most other countries — but it also means navigating a market with less published English-language clinical literature.
The Ultraformer MPT, commonly known in Korean clinics as Shurink (슈링크), is Classys's 4th-generation HIFU device. According to Classys's 2024 disclosures reported by Korea Biomed, cumulative domestic installations have surpassed 2,000 units, reinforcing the manufacturer's reported No. 1 position in the Korean HIFU device market.
MPT vs the previous Ultraformer III — the technical shift that matters:
The headline difference between the earlier Ultraformer III and the current MPT generation is micropulsed technology. Where Ultraformer III deposited roughly 17 thermal coagulation points (TCPs) per treatment line, MPT deposits approximately 417 micropulsed coagulation points per line. The per-point energy is lower, but the coverage density is dramatically higher. The clinical consequence is threefold: (1) treatment time drops by up to 50% for equivalent coverage, (2) patient-reported pain is generally lower because no single point delivers a high-fluence spike, and (3) the thermal injury pattern is denser and more uniform, which may translate into a more even wound-healing response. The same micropulsed architecture is what enables Shurink Universe to cover a full face in roughly 20–30 minutes rather than the 45–60 minutes typical of older generation devices.
Cartridge depths and clinical indications:
Clinical evidence — growing, Korean-authored, increasingly quantified:
Kim JS (2024, Plast Reconstr Surg Glob Open, PMID: 39372881) used 3D scanner analysis on 50 patients (ages 34–81) treated with Ultraformer MPT across seven facial aesthetic units. Measured lifting: forehead 1.24 mm, crow's feet 2.25 mm, malar region 2.46 mm, posterior cheek 3.40 mm, jowl 2.90 mm, mandible 3.09 mm, neck 3.53 mm. All measurements were statistically significant (P < 0.05). This is one of the few published HIFU studies using objective 3D imaging rather than photographic rater grading.
Park H et al. (2015, Ann Dermatol, PMID: 26719637) studied HIFU for wrinkles and laxity in 20 Korean patients across seven facial areas, explicitly on Fitzpatrick III–V Asian skin — demonstrating safety and efficacy particularly in the jawline, cheek, and perioral regions, with only mild transient erythema as the dominant adverse event.
Lio ML et al. (2022, Clin Cosmet Investig Dermatol, PMID: 35368623) evaluated an Ultraformer III multi-depth protocol in 12 Asian patients (Fitzpatrick III–V), quantifying facial rejuvenation with objective measurements and confirming the tolerability of the Classys platform in darker skin types.
Hwang Y et al. (2026, JPRAS Open, DOI: 10.1016/j.jpra.2025.10.036) evaluated a single session of Ultraformer MPT (2.0 mm, 4 MHz) on 34 Korean women (31–67 yo) with mild-to-moderate eyelid laxity. Eyelid length decreased by 0.94 ± 0.34 mm at 12 weeks (P < 0.0001); 76% of patients reported clinical improvement, 59% rater-confirmed. Side effects were limited to mild pain and erythema resolving in 3–4 days.
The Korean HIFU evidence base is smaller than Ultherapy's 50+ peer-reviewed studies — a fact worth acknowledging rather than ignoring — but it is growing, it is authored by Korean-practice investigators, and a meaningful share of it now uses objective outcome measures (3D scanning, blinded rater grading) rather than industry-open-label satisfaction surveys.
Doublo Gold (Hironic):
Doublo Gold was one of the first Korean HIFU devices to reach wide clinical adoption, and Hironic reports (per manufacturer disclosure, not independently verified) that cumulative treatments on the platform have exceeded 1 million since its 2011 launch. Its main technical distinction is bidirectional firing — the transducer emits ultrasound in two directions per pulse instead of one, which in practical terms reduces the number of passes needed to cover a given facial region and roughly halves session time compared to earlier unidirectional designs.
Clinically, Doublo Gold targets the same three-depth MFU paradigm (1.5 / 3.0 / 4.5 mm) as Ultherapy and Ultraformer. Doublo holds CE marking and MFDS (Korea) approval, and is widely available across Asian markets, but it is not FDA-cleared. The published peer-reviewed evidence specifically for Doublo is thinner than for Ultraformer — most Korean HIFU publications (Park 2015, Kim 2024, Hwang 2026, Lio 2022) evaluate the Classys Ultraformer line. For Doublo-specific outcomes, most of the evidence is internal clinical series and conference posters rather than indexed peer-reviewed journal articles.
ULTRAcel Q+ (Jeisys):
ULTRAcel Q+ is a hybrid platform combining HIFU with fractional radiofrequency microneedling in a single device. The clinical rationale is to address both structural lift (via HIFU to the SMAS) and dermal remodeling (via RF microneedling to the mid-dermis) in adjacent sessions without swapping devices. Jeisys holds MFDS approval and CE marking. For international patients: ULTRAcel is a reasonable alternative in clinics that do not carry a dedicated Ultraformer or Doublo, but the HIFU module should not be assumed equivalent to Ultraformer MPT for SMAS-level lifting without asking for specific device settings.
The Chinese-manufactured HIFU warning — evidence-based skepticism, not xenophobia:
A wave of inexpensive HIFU devices manufactured in mainland China has entered Asian aesthetic markets in the past 5 years. The concern is not national origin — Korean HIFU devices are themselves made in Korea, and Korean regulatory pathways (MFDS) are substantively rigorous. The concern is regulatory pathway and published evidence base:
A 2020 systematic review of HIFU (Ayatollahi A et al., Lasers Med Sci, PMID: 32026164) that pooled 17 clinical studies across 477 patients found HIFU to be safe and moderately effective — but this evidence base overwhelmingly reflects Korean, Japanese, European, and North American manufacturer platforms, not uncharacterized Chinese-market devices. The 2025 comprehensive HIFU review by Haykal D et al. (Aesthet Surg J, PMID: 40184185) reached similar conclusions across 45 trials — and again, the trials driving the conclusion are from established platforms, not the budget-tier Chinese devices marketed at mobile "HIFU pens" and non-physician outlets.
When a Seoul clinic offers a HIFU session at a price meaningfully below the market range for Ultraformer MPT or Doublo Gold, asking for the device's manufacturer name and MFDS registration number is reasonable and appropriate.
A necessary caveat before the table: No published head-to-head randomized trial has directly compared Ultherapy with any Korean HIFU device, and no RCT has compared Ultraformer MPT with Doublo Gold. The specifications below are synthesized from manufacturer documentation, Korean-authored clinical series (Park 2015, Kim 2024, Hwang 2026, Lio 2022), and the two HIFU systematic reviews (Ayatollahi 2020, Haykal 2025). Treat it as an orientation tool, not a scoring chart.
| Ultherapy Prime | Ultraformer MPT (Shurink Universe) | Doublo Gold | Ultraformer III (previous generation) | |
|---|---|---|---|---|
| Manufacturer | Merz Aesthetics (US/Germany) | Classys (Korea) | Hironic (Korea) | Classys (Korea) |
| Generation / year | Prime, updated 2020; platform since 2009 | 4th generation, 2020 | Platform since 2011 | 3rd generation, ~2015 |
| TCPs per treatment line | ~20 (discrete, imaging-guided) | ~417 (micropulsed) | Bidirectional dual-point (manufacturer spec) | ~17 (discrete) |
| Cartridge depths (mm) | 1.5 / 3.0 / 4.5 | 1.5 / 2.0 / 3.0 / 4.5 (optional 6.0+) | 1.5 / 3.0 / 4.5 | 1.5 / 3.0 / 4.5 |
| Full-face session time | 60–90 min | 20–30 min | 20–40 min | 45–60 min |
| Real-time imaging | Yes (DeepSEE, to 8 mm) | No | No | No |
| Regulatory | FDA 510(k), MFDS, CE | MFDS, CE — not FDA | MFDS, CE — not FDA | MFDS, CE — not FDA |
| Published evidence | 50+ peer-reviewed studies, meta-analysis of 42 trials (Amiri 2025) | Kim 2024 (3D, n=50), Hwang 2026 (eyelid, n=34) | Limited peer-reviewed, mostly manufacturer-reported | Lio 2022 (n=12 Asian), broader older literature |
Sources for this table: Merz Aesthetics Ultherapy Prime documentation; Classys Ultraformer MPT user manual and 2024 Korea Biomed disclosure; Hironic Doublo Gold specifications (manufacturer); Park 2015 (Ann Dermatol, PMID: 26719637); Kim 2024 (PRS Glob Open, PMID: 39372881); Hwang 2026 (JPRAS Open); Lio 2022 (Clin Cosmet Investig Dermatol, PMID: 35368623); Amiri 2025 (PMID: 39540440).
The most common question international patients ask is whether Korean HIFU is "as good as" Ultherapy. The honest answer is that they solve the same mechanical problem (non-invasive heating at 1.5 / 3.0 / 4.5 mm) with meaningfully different tradeoffs — and no published head-to-head trial lets anyone cite a single winner.
Where Korean HIFU holds real advantages:
Where Ultherapy holds real advantages:
The honest caveat every international patient deserves to hear:
There is no published head-to-head randomized controlled trial comparing Ultherapy with any Korean HIFU device. Every claim that one is "better" than the other — including claims in this guide, in clinic marketing, and in online reviews — is based on indirect comparison across separate single-arm studies with different cohorts, different outcome measures, and different follow-up windows. The 30–50% price differential between Ultherapy and Korean HIFU reflects regulatory pathway cost (FDA maintenance is expensive), imaging hardware (DeepSEE is a significant device-cost line item), and the published-evidence investment Merz has made over 15+ years. It is not an automatic quality differential, and it is not a reason to assume Ultherapy will produce better results on your specific face than a well-executed Ultraformer MPT session by an experienced dermatologist.
Conversely, the lower Korean HIFU price is not a reason to assume Ultherapy is overpriced marketing. Patients sensitive to regulatory depth, real-time imaging guidance near nerves, and the largest published evidence base have a rational basis for choosing Ultherapy. Patients prioritizing speed, cost, and frequency-of-maintenance have a rational basis for Korean HIFU. Both choices are defensible — the indefensible choice is picking based on marketing hyperbole in either direction.
If you're traveling to Seoul for HIFU treatment, here are practical considerations that most clinic marketing won't tell you:
At Gangnam Delight Dermatology, we explain the specific device, cartridge selection, and treatment protocol during consultation — so you understand exactly what you're receiving and why.
FAQ
The short answer is that both have favorable documented safety profiles — but no published head-to-head trial lets anyone make a categorical ranking. Park et al. (2015, Ann Dermatol) specifically evaluated HIFU in 20 Korean patients across seven facial areas and found only mild, transient effects (erythema, tenderness) resolving within days — no persistent adverse events. The Hwang 2026 eyelid-sagging study (34 Korean women on Ultraformer MPT) reported similarly mild side effects clearing in 3–4 days. Ultherapy's larger evidence base (Amiri 2025 meta-analysis, 42 studies) also reports a favorable safety profile. The meaningful differentiator in practice is operator skill and real-time imaging access — not device nationality. DeepSEE visualization gives Ultherapy a genuine safety advantage near the mandibular nerve and major facial vessels; a skilled Korean HIFU operator mitigates this by anatomical knowledge but cannot see through tissue.
Three structural reasons, none of which are about quality. First, regulatory pathway cost: maintaining FDA 510(k) clearance across multiple indications (brow, neck, décolletage, arms, abdomen) is expensive, and Merz has invested in that pathway for 15+ years. Korean manufacturers have prioritized MFDS and CE approval, which have their own rigorous requirements but lower US-market-access costs. Second, imaging hardware: Ultherapy's DeepSEE real-time ultrasound imaging module is a significant device-cost line item that no Korean HIFU device replicates. Third, the published-evidence investment: Merz has funded 50+ peer-reviewed studies, and that evidence base is bundled into device pricing. None of these cost inputs make Ultherapy automatically better for a given patient — they make it more expensive. The Korean HIFU price advantage is real and is not hiding a quality shortfall, but it also reflects narrower regulatory depth and a smaller peer-reviewed evidence base.
Classys's Ultraformer MPT (branded Shurink Universe in Korea) has the most peer-reviewed indexed literature of any Korean HIFU platform as of 2026. The strongest single paper is Kim JS (2024, Plast Reconstr Surg Glob Open), which used 3D scanner analysis to quantify lifting across seven facial aesthetic units in 50 patients: forehead 1.24 mm, crow's feet 2.25 mm, malar 2.46 mm, posterior cheek 3.40 mm, jowl 2.90 mm, mandible 3.09 mm, neck 3.53 mm — all statistically significant (P < 0.05). Hwang 2026 (JPRAS Open) adds a 34-patient eyelid-specific Ultraformer MPT series; Lio 2022 (Clin Cosmet Investig Dermatol) evaluated the earlier Ultraformer III across Fitzpatrick III–V skin. Doublo Gold's published evidence is thinner — most Doublo outcome data are manufacturer series and conference posters rather than indexed journal articles.
Korean clinical practice typically recommends 2–3 initial sessions spaced 3–6 months apart, then maintenance every 6–12 months — a meaningfully different rhythm from Ultherapy's typical single annual session. The difference is partly mechanical (Korean HIFU devices generally deliver less cumulative energy per session than a full Ultherapy protocol), partly economic (shorter, cheaper sessions naturally cluster), and partly cultural (Korean patients favor incremental, frequent maintenance over annual events). The Kim 2024 study measured outcomes after a single Ultraformer MPT session — meaningful improvement is achievable without stacking — but most Seoul dermatologists plan a follow-up at 3–6 months to top up. For a single-visit medical tourist, a well-executed single session is a defensible choice; for a patient with ongoing access, the multi-session model tends to produce more uniform outcomes than one aggressive event.
The concern is regulatory pathway and published evidence, not national origin. Korean HIFU devices are themselves made in Korea under MFDS oversight — the same regulatory rigor that, for instance, Japanese medical devices receive under PMDA. The specific concern with the low-cost Chinese HIFU devices that have spread through budget Asian aesthetic markets in the past five years is (1) many are not NMPA-registered for cosmetic indications (sold for "research" or "beauty salon" use instead), (2) peer-reviewed clinical trials on the specific device names are minimal to absent on PubMed, and (3) reports in Asian aesthetic forums document a pattern of lower acoustic output than spec — which clinics compensate for by doubling shot counts, worsening both outcomes and safety. The established HIFU literature (Ayatollahi 2020 meta-analysis of 17 trials / 477 patients; Haykal 2025 review of 45 trials) overwhelmingly evaluates Korean, Japanese, European, and North American platforms. When a Seoul clinic offers HIFU meaningfully below the market range for Ultraformer MPT or Doublo Gold, asking for the manufacturer name and MFDS registration number is a reasonable due-diligence step.
Related Procedures
If you need more detail about treatment approach, recovery, or suitability, continue into these procedure pages.
Non-surgical Lifting
Ultherapy Prime in Gangnam by a board-certified dermatologist. FDA-cleared non-surgical lifting for jawline, neck, and brow — same-day treatment available.
Solta Medical · AccuREP Technology
Thermage FLX in Gangnam, Seoul. AccuREP real-time feedback, Comfort Pulse, board-certified dermatologist. Over two decades of clinical evidence.
Anti-Aging Package
Neck tightening package in Seoul — Botox for platysmal bands plus filler for neck creases. Board-certified dermatologist in Gangnam.
Periorbital Tightening
Eye Thermage treatment in Seoul for under-eye laxity, crow's feet, and eyelid support with doctor-led treatment planning in Gangnam.
